Metformin in the Diastolic Dysfunction of Metabolic Syndrome

Insulin Resistance Clinical Trial

— MET-DIME  

Official title:

Metformin in the Diastolic Dysfunction of Metabolic Syndrome: MET-DIME Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02017561
• Other study ID #: 01.00240
• Status: Completed
• Phase: Phase 2
• Start date: January 2014
• Est. completion date: December 2019

Study information

• Verified date: March 2020
• Source: Universidade do Porto
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Metabolic syndrome (MS) is a cluster of risk factors for cardiovascular disease with increasing prevalence worldwide and insulin resistance is central to its pathophysiology and multi-organ deleterious effects. One of the most affected organs, the heart, undergoes a remodeling process with an increase in fibrous tissue that impairs global cardiac function. Considering that myocardial fibrosis increases myocardial stiffness, one important determinant of diastolic function, it probably contributes decisively to subclinical left ventricular diastolic dysfunction (DD) and heart failure with preserved ejection fraction in patients with MS.

Since insulin resistance is a dominant player in the pathophysiology of MS, improvement of the metabolic profile of these patients with metformin might be associated with favorable remodeling of myocardial structure and an improvement in myocardial function. Metformin is a widely used drug to treat type 2 diabetes mellitus and is considered an option in the treatment of high-risk non-diabetic patients with MS, in addition to lifestyle counseling including a healthy diet and physical activity.

In this way, we aim to: i) assess if treating non-diabetic patients with MS and DD with metformin in addition to lifestyle counseling decreases cardiac fibrosis and improves diastolic function and assess its impact in functional capacity and health-related quality of life (HRQoL); ii) evaluate if biomarkers of cardiac remodeling and inflammation are predictive factors of response to metformin treatment in these patients.

This is a prospective, randomized, open-label, blinded-endpoint (PROBE) trial (scheduled follow-up of 24 months) with 2 arms: lifestyle counseling only and lifestyle counseling plus metformin (maximum dose of 1000mg twice daily).

The primary endpoint will be change in change in mean of septal and lateral early diastolic mitral annular velocities (E') (at the end of the 24 months of follow-up).

The secondary endpoints will include a composite of major cardiovascular events; diastolic function parameters at rest; plasma levels of insulin, glucose, insulin resistance index, NTproBNP, high-sensitivity C-reactive protein, tumor necrosis factor-α (TNFα), tissue inhibitor of matrix metalloproteinase type 1 (TIMP1) and growth differentiation factor-15 (GDF-15); functional capacity; epicardial, pericardial and abdominal adipose tissue volumes, and coronary calcium score; HRQoL.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 54
• Est. completion date: December 2019
• Est. primary completion date: December 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 64 Years

Eligibility

Inclusion Criteria:

• Non-diabetic adults aged between 40 and 64 years fulfilling the American Heart Association/National Heart, Lung and Blood Institute diagnostic criteria of metabolic syndrome (at least 3 of the following: waist circumference =102 cm (males) or =88 cm (females); fasting triglycerides=150 mg/dL or on drug therapy for decreasing triglycerides; fasting HDL-cholesterol ?40 mg/dL (males) or ?50 mg/dL (females) or on drug therapy for increase HDL-c; systolic blood pressure =130 mmHg or diastolic blood pressure =85 mmHg or on antihypertensive drug therapy; fasting glycemia=100 mg/dL

• Echocardiographic evidence of left ventricle diastolic dysfunction at rest (mean E'?10,2 cm/s if 40-59 years and ?7,2 cm/s if 60-64 years).

Exclusion Criteria:

• diagnosis of diabetes mellitus according to the American Diabetes Association criteria;

• previous diagnosis of ischemic heart disease;

• moderate or severe cardiac valvular disease;

• left ventricle ejection fraction lower than 50%

• pericardial disease;

• uncontrolled atrial or ventricular tachyarrhythmias;

• chronic kidney disease (estimated creatinine clearance lower than 60 mL/min);

• significant liver disease (aspartate aminotransferase or alanine aminotransferase equal or above 2.5 times the upper limit of normal);

• females who are pregnant, planning to become pregnant or who admit sexual activity without appropriate contraception;

• lactation;

• unable to perform cardiopulmonary exercise test;

• recent (less than 1 month) change in drug therapy.

Related Conditions & MeSH terms

• Diastolic Dysfunction
• Insulin Resistance
• Metabolic Syndrome
• Metabolic Syndrome X
• Syndrome

Intervention

Behavioral:
• Lifestyle Counseling
Written and individualized information during the interview in all clinic visits, emphasizing the importance of a healthy lifestyle, engaging on regular moderate-intensity physical activity and eating an healthy diet.

Drug:
• Metformin
Metformin treatment titrated to a maximum dose of 1000mg twice a day. Metformin treatment will start with 500mg at breakfast during the first week and, if well tolerated, increased to 500mg twice a day (breakfast and dinner) in the second week, 1000mg at breakfast and 500mg at dinner in the third week and finally for the target dose of 1000mg twice a day.

Locations

Country	Name	City	State
Portugal	Gaia/Espinho Hospital Centre	Vila Nova de Gaia

Sponsors (3)

Lead Sponsor	Collaborator
Universidade do Porto	Centro Hospitalar de Vila Nova de Gaia/Espinho, Merck Serono International SA

Country where clinical trial is conducted

Portugal, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in mean early diastolic mitral annular velocity (cm/s)	Change in mean of septal and lateral early diastolic mitral annular velocities (E'), assessed by tissue doppler echocardiography	Baseline, 6,12 and 24 months
Secondary	Major adverse cardiovascular events	Composite outcome of major cardiovascular events: nonfatal myocardial infarction, nonfatal stroke, death judged to be due to cardiovascular causes, hospitalization for heart failure, angina confirmed by ischemic changes on exercise tolerance testing or by clinically significant obstruction on coronary angiography or need for revascularization with angioplasty or coronary-artery bypass grafting.	12 and 24 months
Secondary	Diastolic echocardiographic parameters	E/E´ ratio, isovolumetric relaxation time (IVRT), E/A ratio, mitral deceleration time, grade of diastolic dysfunction according to the consensus document of the American Society of Echocardiography and European Society of Echocardiography, strain rate during isovolumetric relaxation (SR-IVR) and E/SR-IVR ratio.	Baseline, 6, 12, 24 months
Secondary	Plasma levels of inflammatory and metabolic biomarkers	Plasma levels of insulin, glucose, insulin resistance index, NTproBNP, high-sensitivity C-reactive protein, TNFa, TIMP1 e GDF-15 (growth differentiation factor 15).	Baseline, 6, 12, 24 months
Secondary	Functional capacity during cardiopulmonary exercise test	Functional capacity during cardiopulmonary exercise test: all patients will perform a symptom-limited treadmill exercise testing according to modified Bruce protocol, with simultaneous respiratory gas analysis. Peak oxygen uptake, anaerobic threshold and ventilatory efficiency will be determined.	Baseline, 12, 24 months
Secondary	Epicardial, pericardial and abdominal adipose tissue volumes	Cardiac multidetector CT without contrast administration to measure epicardial, pericardial and abdominal adipose tissue volumes	Baseline, 24 months
Secondary	Coronary artery calcium quantification	Cardiac multidetector CT without contrast administration to assess coronary artery calcification (calcium score)	Baseline, 24 months
Secondary	Healthcare related quality of life	The Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) will be used to assess general health status and HRQoL.	Baseline, 12, 24 months